Vesna Eraković
GlaxoSmithKline
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Vesna Eraković.
European Journal of Pharmacology | 2001
Ognjen Čulić; Vesna Eraković; Michael J. Parnham
Macrolides are widely used as antibacterial drugs. Clinical and experimental data, however, indicate that they also modulate inflammatory responses, both contributing to the treatment of infective diseases and opening new opportunities for the therapy of other inflammatory conditions. Considerable evidence, mainly from in vitro studies, suggests that leukocytes and neutrophils in particular, are important targets for modulatory effects of macrolides on host defense responses. This underlies the use of the 14-membered macrolide erythromycin for the therapy of diffuse panbronchiolitis. A variety of other inflammatory mediators and processes are also modulated by macrolides, suggesting that the therapeutic indications for these drugs may be extended significantly in future.
European Journal of Pharmacology | 2002
Ognjen Čulić; Vesna Eraković; Ivana Čepelak; Karmela Barišić; Karmen Brajša; Željko Ferenčić; Ružica Galović; Ines Glojnarić; Zoran Manojlović; Vesna Munić; Renata Novak-Mirčetić; Verica Pavičić-Beljak; Mirna Sučić; Marija Veljača; Tihana Žanić-Grubišić; Michael J. Parnham
Effects on human neutrophils and circulating inflammatory mediators were studied in 12 volunteers who received azithromycin (500 mg/day, p.o.) for 3 days. Blood was taken 1 h before treatment, 2.5, 24 h and 28 days after the last dose. An initial neutrophil degranulating effect of azithromycin was reflected in rapid decreases in azurophilic granule enzyme activities in cells and corresponding increases in serum. The oxidative response to a particulate stimulus was also acutely enhanced. These actions were associated with high plasma and neutrophil drug concentrations. A continuous fall in chemokine and interleukin-6 serum concentrations, within the non-pathological range, accompanied a delayed down-regulation of the oxidative burst and an increase in apoptosis of neutrophils up to 28 days after the last azithromycin dose. Neutrophils isolated from blood at this time point still contained detectable drug concentrations. Acute neutrophil stimulation could facilitate antibacterial effects of azithromycin, while delayed, potentially anti-inflammatory activity may curtail deleterious inflammation.
Antimicrobial Agents and Chemotherapy | 2005
Martina Bosnar; Željko Kelnerić; Vesna Munić; Vesna Eraković; Michael J. Parnham
ABSTRACT Macrolide antibiotics have an outstanding ability to concentrate within host cells, particularly phagocytes. In the study described in this paper five different macrolide antibiotics were compared regarding the uptake and release kinetics in human peripheral blood polymorphonuclear neutrophils (PMNs) and three different cell lines, two phagocytic cell lines (RAW 264.7 and THP-1) and an epithelial cell line (MDCK). Based on the results obtained, the substances tested could be clustered into different groups. Azithromycin constituted the first group, characterized by rapid and nonsaturable uptake into phagocytic cells and a high degree of retention in the preloaded cells. The second group included erythromycin and clarithromycin. These two substances do not exhibit cell specificity; consequently, they are taken up to a similar extent and are released by all cell types studied. Ketolides constituted the last group. Their uptake was saturable in cells of monocytic lineage as well as in nondifferentiated cells of myeloid lineage, and they were rapidly released from all the cell lines studied. However, in PMNs, ketolide uptake was not saturable; and unlike telithromycin, cethromycin rapidly egressed from the loaded cells.
The Journal of Antibiotics | 2006
Sulejman Alihodzic; Andrea Fajdetić; Gabrijela Kobrehel; Gorjana Lazarevski; Stjepan Mutak; Drazen Pavlovic; Vlado Štimac; Hana Cipcic; Miroslava Dominis Kramarić; Vesna Eraković; Andreja Hasenöhrl; Nataša Maršić; Wolfgang Schoenfeld
A series of 3-keto and 3-O-acyl derivatives of both 6-O-alkyl-8a-aza-8a-homoerythromycin A and 6-O-alkyl-9a-aza-9a-homo-erythromycin A were synthesised and tested against Gram-positive and Gram-negative bacteria. Derivatives of 8a-aza-8a-homoerythromycin A have potent antibacterial activity against not only azithromycin-susceptible strains, but also efflux (M) and inducible macrolide-lincosamide-streptogramin (iMLSB) resistant Gram-positive pathogens, while the corresponding 9a-isomers were less active. Introduction of an additional ring such as 11,12-cyclic carbonate reduced antibacterial activity of both series. 3-Keto and 3-O-(4-nitrophenyl)acetyl derivatives of 6-O-methyl-8a-aza-8a-homo-erythromycin A show typical macrolide pharmacokinetics in preliminary in vivo studies in mice, and their in vivo efficacy is demonstrated.
European Journal of Pharmacology | 2006
Vanesa Ivetić Tkalčević; Berislav Bošnjak; Boška Hrvačić; Martina Bosnar; Nikola Marjanovic; Željko Ferenčić; Kristina Šitum; Ognjen Čulić; Michael J. Parnham; Vesna Eraković
European Journal of Pharmacology | 2005
Michael J. Parnham; Ognjen Čulić; Vesna Eraković; Vesna Munić; Sanja Popović-Grle; Karmela Barišić; Martina Bosnar; Karmen Brajša; Ivana Čepelak; Snježana Čužić; Ines Glojnarić; Zoran Manojlović; Renata Novak-Mirčetić; Katarina Orešković; Verica Pavičić-Beljak; Senka Radošević; Mirna Sučić
Archive | 2002
Ognjen Čulić; Michael J. Parnham; Vesna Eraković
Archive | 2006
Ognjen Čulić; Martina Bosnar; Nikola Marjanović; Dubravko Jelić; Sulejman Alihodzic; Vanja Vela; Zorica Marusic-Istuk; Vesna Eraković; Berislav Bošnjak; Boška Hrvačić; Marija Tomaskovic; Vanesa Munic; Vanesa Ivetic; Antun Hutinec; Goran Kragol; Marija Leljak
Archive | 2002
Ognjen Čulić; Michael J. Parnham; Vesna Eraković
Archive | 2006
Ognjen Čulić; Martina Bosnar; Nikola Marjanović; Vesna Eraković; Dubravko Jelić; Donatella Verbanac